Interventions and Treatment Modalities
Matching intervention to need
Interventions span biological, psychological, social, and environmental domains. Psychopharmacology requires knowing indications, expected onset, adverse effects, monitoring, and interactions. SSRIs and SNRIs take weeks for full effect and carry serotonin syndrome and discontinuation risks; antipsychotics require monitoring for extrapyramidal symptoms, akathisia, tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, and metabolic effects; clozapine requires white-cell monitoring; lithium requires level and renal/thyroid monitoring plus toxicity education; mood stabilizers and benzodiazepines carry teratogenic, sedative, and dependence risks. Never stop psychotropics abruptly.
Psychotherapies differ: CBT targets thoughts and behaviors, DBT builds distress tolerance and emotion regulation, psychodynamic work explores patterns, and family therapy addresses systems. ECT, TMS, and ketamine are evidence-based for specific conditions and require informed consent and monitoring. Milieu therapy uses structure, safety, and therapeutic community; group work uses universality, altruism, and interpersonal learning. Crisis intervention is brief, focused, and stabilizing; restraint or seclusion is a last resort, time-limited, monitored, debriefed, and governed by law and policy. Harm reduction and integrated treatment for co-occurring disorders meet people where they are.
Traps: expecting immediate antidepressant benefit; interpreting akathisia as "worsening anxiety"; missing NMS (rigidity, hyperthermia, altered consciousness, autonomic instability) versus serotonin syndrome (clonus, hyperreflexia, agitation); advising abrupt benzodiazepine cessation; and assuming insight or adherence follows education alone.
Worked example. A client on haloperidol is restless and pacing, with normal vital signs. Rule of thumb: consider akathisia, not anxiety or noncompliance; report it and anticipate dose review or an anticholinergic or beta-blocker, because untreated akathisia raises suicide and dropout risk.